INTRODUCTION
Gene therapy (GT) has been examined as a new therapeutic method for patients with peripheral arterial occlusive disease. Vascular endothelial growth factor (VEGF)-mediated GT has shown promising results in animal models and in clinical studies by increasing angiogenesis and formation of collateral vessels around the obstructed artery, and thus improving perfusion in the ischemic muscle. [1] [2] [3] [4] The most pressing safety concerns of GT have been the possibility of VEGF acting as a cell proliferative growth factor to accelerate tumor growth or complications of diabetes, such as retinopathy, and atherosclerotic plaque formation as well as immunological responses. [1] [2] [3] [4] With viral vectors in particular, transient immunological reactions, such as fever and elevation in blood C-reactive protein and antibody levels, have been detected. 1, [3] [4] [5] [6] Transient peripheral edema due to increased perfusion and changes in tissue permeability in the treated limb is a relatively common side effect, which apart from subjective discomfort has not caused any severe complications in clinical studies. 1, 4, 7 Serious adverse effects, where treated patients have developed severe life-threatening reactions or cancer, have been rare and mostly related to the use of more pathogenic viral vectors like retroviruses and substantially higher viral dosages. [8] [9] [10] In various short-term studies, plasmid/liposome and adenovirus-mediated VEGF GT has been shown to be safe and well tolerated. [1] [2] [3] [4] [5] [11] [12] [13] [14] [15] [16] In spite of many short-term safety studies, there is limited data available about the safety and possible adverse effects over longer periods of time. We have recently shown that local intracoronary VEGF-A GT using plasmid/liposome and adenoviral vectors does not increase the incidence of cancer, diabetes or its complications, major cardiac events or arrhythmias compared with a randomized control group in an 8-year follow-up. 17 In this study we analyzed the long-term safety and effects of local catheter-mediated VEGF-A gene transfer to the lower limb arteries. The study population consists of patients who participated in a placebocontrolled peripheral arterial occlusive disease phase II VEGF-A GT trial during the years 1998-2001. 4 In this study 54 patients suffering from claudication or critical lower limb ischemia were recruited. Patients were randomized into three groups of which two received VEGF-A with an adenoviral (VEGF-Adv group) or a plasmid/liposome (VEGF-p/l group) vector and a control group that received Ringer's lactate. Gene transfer was performed simultaneously with a percutaneous transluminal angioplasty (PTA) procedure without a stent application. At 3-month follow-up, control angiographies demonstrated increased vascularity after VEGF gene transfer. In addition, gene transfer proved to be safe and well tolerated during the short follow-up time. 4 The aim of this study was to examine the long-term effects of VEGF gene transfer in terms of safety and other long-term effects.
RESULTS

Study population and safety
The study population consists of 54 patients as reported previously. 4 Baseline characteristics are shown in Table 1 . The mean follow-up time was 10 (9-12) years and the mean age at the end of the follow-up was 81.9 (62.6-94.7) years. Twenty-six (48%) patients had died during the follow-up (VEGF-Adv 8/18 vs VEGF-p/l 8/17 vs Control 10/19, respectively; P¼0.88). Causes of death are shown in Table 2 . As for malignancies, one patient in the VEGF-Adv group had died of chronic lymphatic leukemia. In the control group, one patient had died of gastric cancer and one of pulmonary cancer. For four patients (15%) cause of death remains unclear.
A total of 28 (52%) of 54 patients were alive, and 25 of them were reached and interviewed for this study. Two of the patients had been diagnosed with a new cancer during the follow-up time, one control patient had a gastric cancer and one patient in the VEGF-p/l group had a squamous cell carcinoma on skin of the treated leg. Regarding the incidence of cancer within the interviewed patients in the study population, no statistically significant difference was found between the study groups (P¼0.5) ( Table 3) .
During the follow-up, four (7%) of the patients had lost the treated limb (three in the VEGF-p/l and one in the control group). Amputations had been done because of non-treatable critical ischemia, and all of these patients were among the ones who had died.
Before the gene transfer 15 patients (28%) had pre-existing type 2 diabetes. During the follow-up, there was no significant difference in the incidence of diabetes between the study groups. Eight patients (32%) had been diagnosed with a new type 2 diabetes (VEGF-Adv 3/10 vs VEGF-p/l 3/8 vs Control 2/7, respectively; P¼1.00) and one patient (4%) in VEGF-p/l group had diabetic retinopathy (Table 3. ). New cases of diabetic nephropathy had not occurred in any of the study groups. Considering the high age of the patients, most of them suffered also from other diseases typical to the age group, such as musculoskeletal problems, rheumatic diseases and cataract. However, no significant difference in the incidence of these diseases was detected between the groups.
Other long-term effects Patients were asked to assess their subjective exercise tolerance and severity of clinical signs and symptoms. Answers were classified into groups according to Fontaine classification. 18 Two patients (16%) in both VEGF-Adv and VEGF-p/l groups were symptom-free whereas none of the patients in the control group were completely symptomless. Three patients (12%) from the control group and six patients (24%) in both VEGF-Adv and VEGF-p/l groups suffered from claudication. Three patients (12%) in the control group had rest pain and one (4%) had ischemic ulcers, whereas two patients (8%) in the VEGF-Adv group had ulcers at the time of the interview. The difference between the groups was not significant (P¼0.43) ( Table 4) .
During the follow-up, 10 (40%) of the 25 patients interviewed had undergone diagnostic angiography because of ischemic symptoms of the previously treated limb (VEGF-Adv 4/10 vs VEGF-p/l 2/8 vs Control 4/10, P¼0.45). PTA was performed simultaneously with angiography in all other occasions except with one patient in the control group. Surgical revascularization was performed in one patient in the VEGF-Adv group and one in the control group. In terms of angiographies (P¼0.16), PTA procedures (P¼0.76) or surgical revascularization (P¼0.73), no statistically significant differences were detected between the groups (Table 5) .
DISCUSSION
In this study we have shown that adenovirus or plasmid/liposomemediated intravascular local gene transfer does not increase the risk of malignancy, diabetes or any other disease in a long, 10-year follow-up period. Thus, the results of this study further confirm the results of our previous 8-year follow-up in coronary artery disease patients treated with intracoronary VEGF-A GT. 17 Nearly half of the entire patient population died during the followup. For this reason the number of patients interviewed for this study was relatively low. The mortality rate in patients with intermittent claudication is at least two to three times higher than that of age-and sex-matched controls 19 and even much higher mortality among critical limb ischemia patients is well known and documented. 20, 21 In addition, high age and long follow-up time further raised the mortality in the study population. There was no statistically significant difference in Fontaine classification between the VEGF-treated groups and the control group as was also the case when the number of angiographies, PTA procedures and surgical revascularizations were compared. Exercise tolerance was based on patient's subjective experience of their current status, anklebrachial index or angiography were not used to measure the severity of the disease.
Regarding malignancies, no difference among the groups was detected, nor was the incidence higher than that in the general population. The mean age of the patients was high, 81.9 years, at the time of the study yet the incidence of malignancy is still low when compared with the general population, 16 which seems to negate strongly the fear of transient VEGF GT accelerating cell proliferation and tumor growth. 9, 22, 23 The incidence of new cases of diabetes was equal in all study groups, suggesting that GT does not increase the risk. In addition, we did not detect any increase in the incidence of diabetic retinopathy or arthritic lesions, which at least theoretically might occur years after growth factor gene delivery. 15, 24 However, because of the small number of patients in this study, further longterm investigations with larger patient populations will be needed to confirm the results.
A key element for safe gene transfer is local delivery to the treatment site, which reduces the risk of systemic spread of the vector as well as the risk of adverse effects in other organs. Viruses have been verified to have naturally the highest ability to enter cells and also the longest gene expression time. Plasmid/liposome vectors are on one hand less efficient than viral vectors, but are on the other hand less prone to cause immunological responses. The aim of vector development is to create a vector that combines the positive features of each vector type to increase gene transfer efficiency and to diminish host immune responses. This is particularly important when treating genetic diseases and immunodeficient patients but it also reduces the risks in patients with cardiovascular diseases. 9, 10 VEGF-A and its different isoforms are the most commonly used growth factors, and their potential to increase angiogenesis and muscle perfusion in animal models and humans is well established. 3, 4, 12, 23, 25 Improved vascularity and perfusion have been reported in both animal models and clinical trials. However, results in clinical trials have not been as promising as could have been assumed based on animal models. [26] [27] [28] Possible answers to this problem have been tested, such as a combination of several different VEGF-isoforms 5 or suppression of endothelial inflammation in atherosclerotic arteries to enhance the effects of VEGF. 29 In addition, ultrasound has been used at the gene delivery site during gene transfer to enhance angiogenesis, 30 and use of angiogenetic growth factors in combination with stem cells has also shown promising results. 31 In conclusion, our results suggest that local, intravascular VEGF-GT is safe and well tolerated over long periods of time.
PATIENTS AND METHODS
Patient selection and gene transfer
The trial patients were selected for this randomized study as reported earlier. 4 In brief, symptomatic patients with angiographically proven atherosclerotic infrainguinal stenosis or occlusion suitable for PTA were included. Exclusion criteria were type I diabetes, malignancy, osteomyelitis, fertile women, age o50 years, signs of active inflammation, abnormal prostate-specific antigen or carcinoembryonic antigen values and poor cooperation. Each patient signed a written informed consent. Patients were randomized into three groups: VEGF-Adv, VEGF-p/l and Ringer's lactate control group. The treatment and original follow-up for 3 months were made in a double-blinded manner and the patients were randomized at the beginning of the study in blocks of nine patients into the groups. The study was carried out at the Kuopio University Hospital. The trial was approved by the Ethics Committee of the University of Kuopio and the Finnish Agency for Medicinal Products.
Replication-deficient human clinical-grade E1-E3-deleted first-generation adenoviruses were used as viral vectors. Adenoviruses containing a VEGF-A 165 expression cassette were produced as described. 32 Viruses were analyzed for the integrity and absence of replication-competent adenoviruses using E1-and E2-specific PCRs, Southern blot analysis and a cytopathic effect assay on A549 cells. VEGF-p/l was manufactured by complexing 2000mg pCMV-hVEGF 165 (GenBank accession no. AB021221) plasmid with 2000 ml of DOTMA:DOPE (1 mg ml À1 , 1:1. Valentis Inc., Burlingame, CA, USA) and mixing with 1000 ml Ringer's solution. 33 Plasmids and adenoviruses were tested to be free of any microbiological contaminants and endotoxin (o20 EU/dose, Whittaker, Walkersville, MD, USA). Selective digital subtraction angiography and intravascular ultrasound were conducted as described. 4 Gene transfer and control procedure were performed at the site of PTA using an infusionperfusion coil-balloon catheter (Dispatch catheter, Boston Scientific, Natick, MA, USA) for infrapopliteal lesions and a channeled-balloon catheter (Remedy, Boston Scientific/MediTech, Natick, MA, USA) for femoropopliteal lesions. Patients were followed at the hospital for 2 days and invited for follow-up visits 1-3 months after the gene transfer. The short-term follow-up details and results have been reported. 4 Table 4 Severity of ischemic symptoms according to Fontaine classification at randomization and at follow-up interview, n¼25 
Long-term follow-up
Patients were interviewed by telephone or a questionnaire letter, if not reached by telephone. Questions were focused on their current state of health, working ability, exercise tolerance, occurrence and severity of possible limb ischemia (claudication, rest pain, ischemic ulcer, amputation) and angina pectoris. Angiographies, PTA procedures, operations or possible amputations performed on the treated limb after the initial procedures were clarified from hospital records. Malignancies, diabetes or its complications and any other significant diseases diagnosed during the follow-up period were recorded. In addition, accuracy of the information provided by the patients was further verified from hospital records. Finnish Population Register Center provided the information on patients having died during the follow-up and the causes of death were obtained from regional hospitals and health centers according to the ICD-10 (International Classification of Diseases) codes. Statistical analysis was performed using w 2 -test. As the number of patients in this study was relatively small, exact feature was used together with w 2 . Linear mixed models test was used to compare differences in Fontaine classification between the groups. Statistical analysis was performed using SPSS statistical software (v17.0, SPSS Inc., Chicago, IL, USA). Results were considered statistically significant at Po0.05.
